Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium
27 June 2023 - 10:30PM
Artelo Biosciences,
Inc.
(Nasdaq: ARTL), a
clinical-stage pharmaceutical company focused on modulating
lipid-signaling pathways to develop treatments for people living
with cancer, pain, and neurological conditions, announced that
Professor Saoirse O’Sullivan, Vice President of Translational
Sciences at Artelo, presented preclinical data related to ART26.12,
Artelo’s novel fatty acid binding protein 5 (FABP5) inhibitor at
the 33rd International Cannabinoid Research Society (ICRS)
Symposium in Toronto, Ontario, Canada.
“Growing evidence of ART26.12’s activity on neuropathic pain
caused by various chemotherapies or diabetes further substantiates
developing our potent and novel FABP5 inhibitor as an innovative
new treatment for painful neuropathies,” said Gregory D. Gorgas,
Artelo’s President and Chief Executive Officer. There are very
limited therapeutic options currently available and these existing
treatments are often associated with a significant and undesirable
side effect profile. According to Coherent Market Insights, the
global neuropathic pain market is estimated to be valued at $7.6
billion. “We are making substantial progress in advancing this
important program towards the clinic and are looking forward to
receiving pre-IND meeting minutes from the FDA during the third
quarter of this year, which will mark a substantial milestone for
ART26.12,” added Mr. Gorgas.
“ART26.12 continues to demonstrate a positive effect in numerous
animal models of painful neuropathies, specifically
chemotherapy-induced peripheral neuropathy (CIPN) and diabetic
neuropathy,” said Professor O’Sullivan. “We were pleased to present
new data with paclitaxel that confirms a previous study with
oxaliplatin-induced CIPN which suggests a common mechanism of
action of ART26.12 that is capable of preventing allodynia from
both taxane- and platinum-based agents, the two most common causes
of CIPN,” continued Professor O’Sullivan “In another animal study,
orally administered ART26.12 demonstrated not only a desirable drug
profile, but impotantly also reduced mechanical hypersensitivity in
painful diabetic neuropathy. Based on these results, we are highly
encouraged by the potential of ART26.12 for the countless patients
suffering from this often excruciating and debilitating
condition.”
About ART26.12Fatty Acid Binding Proteins
(FABPs) are a family of intracellular proteins that chaperone
lipids including endocannabinoids and fatty acids. Various
inhibitors of FABPs may be particularly useful for the treatment of
specific cancers, neuropathic and nociceptive pain, and anxiety
disorders. ART26.12, Artelo’s lead FABP inhibitor compound, is a
selective inhibitor of FABP5. While developing our lead molecule in
painful neuropathies, including for CIPN, we have additional
compounds from our extensive library of potent and selective
inhibitors of FABPs that have been identified and selected for
advancement towards regulatory-enabling studies in cancer and other
areas of high-unmet need where inhibition of FABPs show significant
promise.
About Painful NeuropathiesPeripheral neuropathy
refers to a condition in which there is damage to the peripheral
nerves. These nerves are responsible for transmitting signals
between the central nervous system and the rest of the
body. CIPN is a common and often painfully debilitating
complication of cancer therapies, sometimes resulting in reduction
or cessation of treatment. No currently approved treatment exists
for CIPN. Diabetic Neuropathy refers to a type of nerve
damage that occurs as a complication of diabetes. It is caused by
long-term high blood sugar levels, which can lead to damage of the
blood vessels and nerves throughout the body. The
prevalence of diabetic neuropathy is significant due to the
increasing number of people with diabetes worldwide.
About the International Cannabinoid Research
SocietyThe International Cannabinoid Research
Society (ICRS) is the premier global scientific association
with more than 650 international members from 40 countries, all
active researchers in the field of endogenous, plant-derived, and
synthetic cannabinoids and related bioactive lipids. In addition to
acting as a source for impartial information on cannabis and the
cannabinoids, the main role of the ICRS is to provide an open forum
for researchers to meet and discuss their research. The ICRS
Symposium is being held at the Marriott Downtown at CF Toronto
Eaton Centre, Toronto, Canada, from June 24-29, 2023.
Interested parties may follow @ICRS_Society on
Twitter.
About Artelo BiosciencesArtelo Biosciences,
Inc. is a clinical stage pharmaceutical company dedicated to
the development and commercialization of proprietary therapeutics
that modulate lipid-signaling pathways including the
endocannabinoid system. Artelo is advancing a portfolio of broadly
applicable product candidates designed to address significant unmet
needs in multiple diseases and conditions, including anorexia,
cancer, anxiety, pain, neuropathy, and inflammation. Led by proven
biopharmaceutical executives collaborating with highly respected
researchers and technology experts, the company applies leading
edge scientific, regulatory, and commercial discipline to develop
high-impact therapies. More information is available
at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking StatementsThis press release
contains certain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and Private Securities Litigation
Reform Act, as amended, including those relating to the Company’s
product development, clinical and regulatory timelines, market
opportunity, competitive position, possible or assumed future
results of operations, business strategies, potential growth
opportunities and other statement that are predictive in nature.
These forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management’s current beliefs and
assumptions. These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
“expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements
relate to future events and involve known and unknown risks,
uncertainties, and other factors which may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Such factors include those set
forth in the Company’s filings with the Securities and Exchange
Commission, including our ability to raise additional capital in
the future. Prospective investors are cautioned not to place undue
reliance on such forward-looking statements, which speak only as of
the date of this press release. The Company undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise,
except to the extent required by applicable securities laws.
Investor Relations Contact:Crescendo
Communications, LLCTel: 212-671-1020Email:
ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Apr 2024 to May 2024
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From May 2023 to May 2024